Literature DB >> 10421135

Time course of endothelin-1 and adrenomedullin after the Fontan procedure.

T Hiramatsu1, Y Imai, Y Takanashi, K Seo, M Terada, M Aoki, M Nakazawa.   

Abstract

BACKGROUND: The endothelium-derived vasoconstrictor endothelin (ET)-1 might contribute to the physiology of blood flow regulation and play a role in cardiovascular disease. Adrenomedullin (AM) is a potent vasodilator peptide that has major effects on cardiovascular function and has multiple biologic effects involved in cardiovascular homeostasis. Although pulmonary vascular resistance is known to be one of the most important factors to determine the indications for a Fontan procedure, the time course of the plasma cytokine before and after the Fontan procedure is not known.
METHODS: Sixteen patients were divided into two groups, 8 patients (1 to 14 years) who had the Fontan procedure (atriopulmonary connection) and 8 age-matched controls who had biventricular repair with normal central venous pressure. Plasma ET-1 and adrenomedullin levels were measured in both groups immediately before cardiopulmonary bypass, immediately after cardiopulmonary bypass, and 6 and 24 hours after cardiopulmonary bypass. A thermodilution catheter was inserted during the operation, and mean pulmonary arterial pressure, pulmonary wedge pressure, and cardiac output were measured, and pulmonary vascular resistance was calculated at the same time points. Correlation between the plasma ET-1 levels and pulmonary vascular resistance data were obtained in the Fontan group.
RESULTS: Plasma ET-1 levels in the Fontan group were elevated after operation and were higher than the control group at 6 and 24 hours after cardiopulmonary bypass. Plasma adrenomedullin in the Fontan group was lower than in the control group at 6 and 24 hours after cardiopulmonary bypass. A significant positive correlation was obtained between the plasma ET-1 and pulmonary vascular resistance data (r = 0.475).
CONCLUSIONS: Imbalance between increased ET-1 and relatively decreased adrenomedullin after cardiopulmonary bypass in the Fontan procedure could contribute to dominant effects of ET-1, which might induce vasoconstriction after the Fontan procedure. ET-1 might play an important role in maintaining vasoconstriction after the Fontan procedure.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10421135     DOI: 10.1016/s0003-4975(99)00374-4

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Impact of Nesiritide Infusion on Early Postoperative Recovery After Total Cavopulmonary Connection Surgery.

Authors:  Yajuan Zhang; Yabing Duan; Jun Yan; Qiang Wang; Shoujun Li; Haitao Xu
Journal:  Pediatr Cardiol       Date:  2018-07-12       Impact factor: 1.655

2.  Increased Circulating Endothelin 1 Is Associated With Postoperative Hypoxemia in Infants With Single-Ventricle Heart Disease Undergoing Superior Cavopulmonary Anastomosis.

Authors:  Benjamin S Frank; Ludmila Khailova; Lori Silveira; Max B Mitchell; Gareth J Morgan; Michael V DiMaria; Jesse A Davidson
Journal:  J Am Heart Assoc       Date:  2022-03-04       Impact factor: 6.106

3.  Endothelin-1 activation in pediatric patients undergoing surgical coarctation of the aorta repair.

Authors:  Benjamin Steven Frank; Tracy T Urban; Suhong Tong; Courtney Cassidy; Max B Mitchell; Christopher S Nichols; Jesse A Davidson
Journal:  World J Cardiol       Date:  2017-12-26

Review 4.  The Pulmonary Circulation in the Single Ventricle Patient.

Authors:  Amanda Hauck; Nicolas Porta; Steven Lestrud; Stuart Berger
Journal:  Children (Basel)       Date:  2017-08-07

Review 5.  The pathophysiology and complications of Fontan circulation.

Authors:  Giuseppe Antonio Mazza; Elena Gribaudo; Gabriella Agnoletti
Journal:  Acta Biomed       Date:  2021-11-03

Review 6.  A Review of Adrenomedullin in Pediatric Patients: A Useful Biomarker.

Authors:  Anna Solé-Ribalta; Sara Bobillo-Pérez; Iolanda Jordan-García
Journal:  Children (Basel)       Date:  2022-08-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.